Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Claire Booth1,2, H Bobby Gaspar1,21Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK; 2Dept of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UKAbstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine...
Saved in:
Main Authors: | Claire Booth, H Bobby Gaspar |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/951c4df78fd143a5b421a262ed2ac31b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
by: Federico A. Moretti, et al.
Published: (2021) -
Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency
by: Claudia A Montiel-Equihua, et al.
Published: (2009) -
CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg−/− Mice Results in Severe Immunodeficiency
by: Xinru Wei, et al.
Published: (2017) -
Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients
by: Khan SA, et al.
Published: (2018) - Ada user journal